Accéder au contenu
Merck
  • Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013-12-04)
Charles L Loprinzi, Rui Qin, Shaker R Dakhil, Louis Fehrenbacher, Kathleen A Flynn, Pamela Atherton, Drew Seisler, Rubina Qamar, Grant C Lewis, Axel Grothey
RÉSUMÉ

Cumulative neurotoxicity is a prominent toxicity of oxaliplatin-based therapy. Intravenous calcium and magnesium have been extensively used to reduce oxaliplatin-induced neurotoxicity. This trial was designed to definitively test whether calcium/magnesium decreases oxaliplatin-related neurotoxicity. In all, 353 patients with colon cancer undergoing adjuvant therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were randomly assigned to intravenous calcium/magnesium before and after oxaliplatin, a placebo before and after, or calcium/magnesium before and placebo after. The primary end point was cumulative neurotoxicity measured by the sensory scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 tool. There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale. In addition, calcium/magnesium did not substantially decrease oxaliplatin-induced acute neuropathy. This study does not support using calcium/magnesium to protect against oxaliplatin-induced neurotoxicity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Magnésium, powder, ≥99%
Sigma-Aldrich
Oxaliplatine, powder
Sigma-Aldrich
Magnésium, ribbon, ≥99.0% Mg basis
Sigma-Aldrich
Magnésium, purum, for Grignard reactions, ≥99.5%, turnings
Sigma-Aldrich
Magnésium, chips, 6-35 mesh, 99.98% trace metals basis
Sigma-Aldrich
Folinic acid calcium salt hydrate, BioXtra, ≥99.0% (HPLC)
Sigma-Aldrich
Magnésium, turnings, reagent grade, 98%
Sigma-Aldrich
Magnésium, turnings, 5-25 mm, 99.95% trace metals basis
Sigma-Aldrich
Magnésium, wire, 127 μm diameter, 99.9% trace metals basis
Sigma-Aldrich
Magnesium preparation, Highly Reactive Rieke® Metal, suspension, 2.5 g in THF
Sigma-Aldrich
Magnésium, dendritic pieces, purified by distillation, 99.998% trace metals basis
Sigma-Aldrich
Magnésium, grit, ≥99.0% (KT)
Supelco
Folinic acid calcium salt hydrate, analytical standard
Sigma-Aldrich
Magnésium, rod, diam. 6 mm, ≥99.9% trace metals basis
Magnésium, wire reel, 1m, diameter 0.5mm, as drawn, 99.9+%
Calcium folinate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Magnésium, in a Sure/Seal bottle, turnings, anhydrous tetrahydrofuran 37.5 mmol
Oxaliplatine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Magnésium, ReagentPlus®, ribbon, ≥99% trace metals basis
Sigma-Aldrich
Magnésium, 20-230 mesh, reagent grade, 98%
Magnésium, wire reel, 2m, diameter 0.125mm, as drawn, 99.9+%
Magnésium, wire reel, 0.1m, diameter 0.5mm, as drawn, 99.9+%
Sigma-Aldrich
Magnésium, in a Sure/Seal bottle, turnings, 37.5 mmol
Magnésium, wire reel, 0.1m, diameter 0.4mm, as drawn, 99.9+%
Magnésium, wire reel, 0.5m, diameter 0.25mm, as drawn, 99.9+%
Magnésium, wire reel, 0.5m, diameter 1.1mm, as drawn, 99.9+%
Magnésium, wire reel, 0.5m, diameter 0.4mm, as drawn, 99.9+%
Magnésium, wire reel, 0.5m, diameter 1.0mm, as drawn, 99.9+%
Magnésium, wire reel, 1m, diameter 1.1mm, as drawn, 99.9+%
Magnésium, wire reel, 0.1m, diameter 0.125mm, as drawn, 99.9+%